Yogesh N V Reddy, MD, MSc
Disclosures: Consulting Fee-Edwards Life Sciences-Consulting/Advisory Board
PHS 398/2590 (Rev. 06/09), Biographical Sketch Format Page

BIOGRAPHICAL SKETCH

 

NAME

Reddy, Yogesh Nellore Vilambi

 

POSITION TITLE

Assistant Professor in Medicine

eRA COMMONS USER NAME (credential, e.g., agency login)

REDDY1

EDUCATION/TRAINING 

INSTITUTION AND LOCATION

DEGREE

MM/YY

FIELD OF STUDY

Madras Medical College, Chennai, India

MBBS

09/11

Medicine

Case Western Reserve/University Hospitals, Cleveland, OH

 

06/14

Internal Medicine

Mayo Clinic, Rochester, MN

 

06/16

Cardiovascular Diseases

Mayo Clinic, Rochester, MN

MSc

06/18

Biostatistics, Clinical Trial Design

Mayo Clinic, Rochester, MN

 

06/18

NIH T32 training grant

Mayo Clinic, Rochester, MN

 

06/19

Advanced Heart Failure and Transplantation

Mayo Clinic, Rochester, MN

 

06/20

Critical Care

Mayo Clinic, Rochester, MN

 

07/20

Senior Associate Consultant

 

APersonal Statement

I am a board certified invasive cardiologist and heart failure specialist, and Senior Associate Consultant in the Circulatory Failure Division and Cardiac Catheterization laboratory at Mayo Clinic. My clinical focus is on heart failure (HF), invasive exercise hemodynamics, pulmonary hypertension and valve disease. I have been an active investigator in the field of HF for the past 6 years, with particular focus on the exercise hemodynamics of HF with preserved ejection fraction (HFpEF) under Dr Barry Borlaug’s mentorship, who is an internationally recognized expert in the field of heart failure, invasive hemodynamics and exercise physiology. I have also had extensive experience and training in the evaluation and management of complex valve disease with Dr Rick Nishimura who is the lead author on the ACC valve guidelines and a globally recognized expert in valve disease and co-investigator on this proposal. I have experience conducting clinical research with more than 120 peer reviewed publications and book chapters and have a Masters in Clinical Investigation.

 

B. Positions and Honors

Positions and Employment

2011-2014      Resident, University Hospitals Case Medical Center, Cleveland, OH

2014-2016               Clinical Fellow, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN

2016-2018              NIH T32 training grant for 2 years of protected research under Dr Barry Borlaug, Rochester, MN

2018-2019              Advanced Heart Failure and Transplantation Fellow, Mayo Clinic, Rochester, MN

2019-2020              Cardiology Critical Care Fellow, Mayo Clinic, Rochester, MN

2020-              Senior Associate Consultant, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN

 

Other Experience and Professional Memberships

2015-                                          Member, Heart Failure Society of America

2014-                                          Member, American College of Cardiology

2014-                                          Member, American College of Physicians

2016-                                          Member of Heart Failure Apprentice Network (HFAN)

2016-                                          Ad Hoc Reviewer for the Journal of American College of Cardiology

2017-                                          Ad Hoc Reviewer for Journal of Cardiac Failure

2018-                                          Ad Hoc Reviewer for AJP- Heart and Circulatory Physiology

2018-                                          Ad Hoc Reviewer for ESC Heart Failure

2018-                                          Ad Hoc Reviewer for Minerva Cardioangiologica

2018-                                          Ad Hoc Reviewer for JACC Heart Failure

2019-                                          Ad Hoc Reviewer for European Journal of Heart Failure

2019-                                          Ad Hoc Reviewer for Circulation Heart Failure

 

Honors and Awards             

2005

100% Scholarship for MD awarded for ranking 67th out of ~200,000 examinees in qualifying examination

2010

Madras Medical College – five gold medals awarded to the best student in Clinical Medicine, Surgery, Internal Medicine, Therapeutics and Tropical Medicine

2010

Honors in Pharmacology, Medicine, Pediatrics and Surgery.

2010

First place – state-level medical quiz at Stanley Medical College, Chennai

2010

First place – All India National Medical Quiz at Apollo Hospital, Chennai

2010

Young investigator traveler grant awarded to present my research on dengue fever and renal outcomes at the 15th International Conference on Continuous Renal Replacement Therapy in San Diego

2012

Medical student teaching award at University Hospitals Case Medical Center

2014

Normon Goodman award presented to the most humanitarian and outstanding clinical resident (University Hospitals Case Medical Center)

2015

Heart Failure Society of America Travel Grant to present my research on High Output Heart Failure at HFSA 2015 in Washington DC

2016

Co-author on paper that resulted in Eric N. Prystowsky Early Career Researcher award to Dr Sundaram. Outcomes with Cardiac Resynchronization Therapy and Standard Implantable Cardioverter Defibrillators in Patients with a Very Wide QRS Duration (QRS > 180 ms): A Medicare ICD Registry Analysis with Propensity Matching. Heart Rhythm Society 2016.

2016-2018

Awarded NIH T32 HL007111 training grant for 2 years of protected clinical research under Dr. Barry Borlaug’s mentorship

2016-2018

Awarded Heart Failure of Society of America training grant to complete a randomized double blind pilot study of albuterol in Heart Failure with Preserved Ejection Fraction and its effect on exercise hemodynamics (Registered on Clinical Trials.gov- NCT02885636)

2017

Heart Failure Society of America Travel Grant to present my research on prevalence of HFpEF among atrial fibrillation at HFSA 2017 in Dallas, TX

2017

Awarded Best Poster Award at American College of Cardiology Meeting 2017 for project on Arterial Reserve Limitations in Heart Failure with Preserved Ejection Fraction and the Beneficial Effects of Sodium Nitrite

2018

Awarded Best Poster Award at American College of Cardiology Meeting 2018 for project on Low Flow, Low Gradient Mitral Stenosis

2018

National Cardiology Jeopardy Champion at ACC 2018

2018

Donald C. Balfour Alumni Award for Meritorious Research which recognizes outstanding research by a resident across all departments of medicine and surgery of Mayo School of Graduate Medical Education.

2018

Finalist in Jay N Cohn Young Investigator Award at Heart Failure Society of America September 2018 for project on randomized trial of albuterol in HFpEF

2018

Co-author on paper selected for Jay N Cohn Young Investigator Award at Heart Failure Society of America September 2018 for project on longitudinal changes in RV function in HFpEF

2018

 

 

2019

 

 

2020-2022

Co-author on paper selected for final of Jay N Cohn Young Investigator Award at Heart Failure Society of America September 2018 for project on the hemodynamic impact of epicardial fat on the obese phenotype of HFpEF

First place in Northwestern Young Investigator Competition (November 2019) for project on hemodynamics of pulmonary congestion during exercise in Heart Failure with Preserved Ejection fraction and the role of the right ventricle

Bayer Accelerated Pulmonary Hypertension Award to fund 2 year project on studying the exercise hemodynamic response of therapy in atypical pulmonary arterial hypertension with risk factors for left heart disease

 

C.  Contributions to Science

  1. The hemodynamics of adverse volume loading on left ventricular function have been well characterized however, its impact on the right ventricle are less well defined. In a series of studies we have evaluated the impact of high output heart failure on cardiac hemodynamics showing several novel associations between obesity, dialysis fistulas and liver disease with high output heart failure. We subsequently demonstrated that dialysis fistulas in particular are associated with more prominent adverse right ventricular remodeling and an associated increased risk of death. However, smaller volume loads on the right ventricle such as those created by iatrogenic atrial septal defects appear to be well tolerated in the short term in selected patients with HFpEF. These observations are important since we also showed in a separate study that adverse RV remodeling appears to be the strongest predictor of poor outcomes in HFpEF and is associated with progressive TR. We also identified novel associations with AF and obesity in driving this adverse RV remodeling. Collectively these investigations have advanced our understanding of the physiology of abnormal volume loading of the heart.
    1. Reddy YN, Melenovsky V, Redfield M, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol. 2016 Aug 2;68(5):473-82.
    2. Reddy YN, Obokata M, Dean P, Nath KA, Borlaug BA. Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease. Eur Heart J. 2017 Mar 6.
    3. Obokata M, Reddy YN, Shah SJ, Kaye DM, Gustafsson F, Hasenfuβ G, Hoendermis E, Litwin SE, Komtebedde J, Lam C, Burkhoff D, Borlaug BA. Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 Nov 26;74(21):2539-2550
    4. Obokata M, Reddy YN, Melenovsky V, Pislaru S, Borlaug BA. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J. 2019 Feb 21;40(8):689-697.

 

  1. Atrial fibrillation (AF) is common in HFpEF but its functional role and relationship with HFpEF has been only partially elucidated. In a series of experiments we have demonstrated that AF frequently represents a form of advanced atrial myopathy with the greatest impairment in Left Atrial (LA) mechanics defined using novel measures such as LA strain. Additionally, the diagnosis of HFpEF non-invasively has been challenging using echo in AF and we demonstrated for the first time a near universal prevalence of deranged central hemodynamics during exercise consistent with HFpEF. This has greatly simplified non-invasive diagnosis of HFpEF and resulted in our development and validation of the H2FPEF score which is now a ESC guideline endorsed method to evaluate for HFpEF and is heavily driven by the presence or absence of AF. Overall, these studies established a close interrelationship between AF, LA remodeling and HFpEF
    1. Reddy YN, Obokata M, Gersh B, Borlaug BA. High Prevalence of Occult Heart Failure with Preserved Ejection Fraction among patients with Atrial Fibrillation and Dyspnea. Circulation. 2018;137:534-535
    2. Reddy YN, Obokata M, Egbe A, Yang JH, Pislaru S, Lin G, Carter R, Borlaug BA. Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction. Eur J Heart Fail. 2019 Jul;21(7):891-900.
    3. Tamargo M, Obokata M, Reddy YN, Pislaru S, Lin G, Egbe AC, Nishimura RA, Borlaug BA. Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection. Eur J Heart Fail. 2020 (in press)
    4. Reddy YN, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861–870.

 

  1. Obesity has been previously recognized as a risk factor for heart failure, but its mechanisms and pathophysiology have been poorly characterized. Through a number of investigations we have conclusively proven the existence of a unique phenotype of obesity related HFpEF where the pathophysiology is driven by pericardial restraint and deranged right ventricular reserve. Importantly, the magnitude of hemodynamic derangement appears proportional to weight gain, and in a meta-analysis of prior hemodynamic research we showed that weight loss may exert favorable effects on hemodynamics. This was subsequently followed by multicenter validation of this phenotype demonstrated worse congestion related symptoms and signs in obese HFpEF, coupled with a younger age, greater inflammation and lower traditional markers of HF severity by natriuretic peptides and left atrial size. Collectively, these studies firmly established the existence of a novel phenotype of HFpEF driven primarily by obesity and excess adiposity with pericardial restraint.
    1. Obokata M, Reddy YN, Borlaug BA. Evidence Supporting the Existence of an Obese Phenotype of Heart Failure with Preserved Ejection Fraction. Circulation. 2017 Jul 4;136(1):6-19
    2. Reddy YN, Anantha-Narayanan M, Obokata M, Koepp KE, Erwin P, Carter RE, Borlaug BA. Hemodynamic Effects of Weight Loss in Obesity: A Systematic Review and Meta-Analysis. JACC Heart Fail. 2019 Aug;7(8):678-687
    3. Reddy YN, Lewis GD, Shah SJ, Obokata M, Abou-Ezzedine OF, Fudim M, Sun JL, Chakraborty H, McNulty S, LeWinter MM, Mann DL, Stevenson LW, Redfield MM, Borlaug BA. Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. Mayo Clin Proc. 2019 Jul;94(7):1199-1209
    4. Reddy YN, Obokata M, Redfield M, Borlaug BA. Quality of Life in Heart Failure with Preserved Ejection Fraction: Importance of Obesity, Functional Capacity, and Physical Inactivity. Eur J Heart Failure 2020 (in press)

 

  1. Pulmonary vascular reserve is known to be abnormal in HFpEF but its functional implications are unclear. We performed a detailed exercise hemodynamic study of HFpEF with pulmonary vascular disease and demonstrated prominent ventricular interdependence during exercise constraining left ventricular filling. We then demonstrated in a prospective double blind randomized trial that I led, that this abnormal pulmonary vasodilator reserve during exercise could be restored by albuterol with improvement in exercise cardiac output and relief of pericardial restraint. We also observed a novel role for endothelin and adrenomedullin in pulmonary hemodynamic derangements. In a separate study we noted associations between exertional pulmonary vascular reserve with exertional dead space ventilation. These studies have therefore advanced our understanding of the role of pulmonary vascular disease and abnormal right ventricular reserve in the pathophysiology of HFpEF
    1. Gorter T, Obokata M, Reddy YN, Melenovsky V, Borlaug BA. Exercise unmasks distinct pathophysiological features of pulmonary vascular disease in Heart Failure with preserved Ejection Fraction. European Heart Journal 2018 Aug 7;39(30):2825-2835
    2. Reddy YN, Obokata M, Koepp KE, Egbe AC, Wiley B, Borlaug BA. The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction. Circ Res. 2019 Jan 18;124(2):306-314
    3. Obokata M, Kane GC, Reddy YN, Melenovsky V, Olson TP, Jarolim P, Borlaug BA. The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction. Eur Heart J. 2019 Dec 1;40(45):3707-3717
    4. Obokata M, Olson TP, Reddy YN, Melenovsky V, Kane GC, Borlaug BA. Hemodynamics, Dyspnea, and Pulmonary Reserve in Heart Failure with Preserved Ejection Fraction. European Heart Journal 2018;39(30):2810–2821

 

  1. The diagnosis of HFpEF remains challenging due to the presence of exertional reserve limitations that may not be apparent at rest. We have extensively studied the physiology of abnormal exercise response in HFpEF using high fidelity micromanometer catheterization with cardiopulmonary exercise testing over the last 5 years with multiple novel observations which have impacted the diagnostic approach to this disease. We demonstrated that hypertension alone was insufficient to identify HFpEF where arterial stiffening often manifested only during exercise, and was associated with matched absolute blood pressure compared to hypertensive controls. These derangements impact myocardial supply-demand mismatch and were associated with myocardial injury and troponin release during exercise. We also showed the limited utility of maximum oxygen consumption testing in identifying HFpEF although there remains a relationship between filling pressures and exercise capacity in both the upright and supine positions during exercise. In a prospective study, we showed that the development of pulmonary edema during exercise appears in about half of HFpEF patients during low level exercise and is associated with elevation in biventricular filling pressures and impaired left atrial and right ventricular reserve. This suggests a novel role for right ventricular dysfunction in the pathogenesis of pulmonary edema potentially through development of right atrial hypertension with impeded lymphatic drainage from the lung.
    1. Reddy YN, Andersen M, Obokata M, Kane G, Olson TP, Borlaug BA. Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2017 Jul 11;70(2):136-148.
    2. Obokata M, Reddy YN, Borlaug BA. Myocardial Injury and Cardiac Reserve Limitation in Heart Failure with Preserved Ejection Fraction. J Am Coll Cardiol 2018 J Am Coll Cardiol. 2018 Jul 3;72(1):29-40
    3. Reddy YN, Olson TP, Obokata M, Borlaug BA. Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure with Preserved Ejection Fraction. J Am Coll Cardiol HF 2018;6(8):665–675
    4. Reddy YN, Obokata M, Wiley B, Koepp KE, Jorgenson CC, Egbe A, Melenovsky V, Carter RE, Borlaug BA. The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction. Eur Heart J. 2019 Dec 1;40(45):3721-3730

 

Published Work in My Bibliography (Publication Count >120): https://www.ncbi.nlm.nih.gov/sites/myncbi/1FSXeC2iZf4Qb/collections/58701531/public/

 

      1. Research Support

Ongoing Research Support

Bayer Accelerated Award               Reddy (PI)              07/01/2020-6/30/2022

Bayer Pulmonary Hypertension Award to fund 2 year project on studying the exercise hemodynamic response of therapy in atypical pulmonary arterial hypertension with risk factors for left heart disease                                                                                                                                                                [$50,000 per year for 2 years, total $100,000]                                                   Role: Principal Investigator

 

Young Investigator Award Grant              Reddy (PI)              01/01/2020 - 01/01/2021

Grant for being awarded First place in Northwestern Young Investigator Competition                               [$1500]                                                                                                                Role: Principal Investigator

 

Mayo CV Prospective Award               Reddy (PI)              01/01/2021-01/01/2023

Mayo Clinic CV Prospective Award to fund 2 year project on studying the exercise hemodynamics of severe tricuspid regurgitation and impact of rhythm control and surgery                                                                                                                                                      [$150,000 per year for 2 years, total $300,000]                                                   Role: Principal Investigator

 

Sleep Number External Grant              Reddy (PI)              01/01/2021-01/01/2023

Grant to study the prevalence and hemodynamic impact of obstructive sleep apnea in Heart Failure with preserved Ejection Fraction

[$150,000 per year for 2 years, total $300,000]                                                   Role: Principal Investigator

 

Sleep Number External Grant              Reddy (PI)              01/01/2021-01/01/2023

Grant to study the sleep characteristics and demographics of subjects with occult Heart Failure with preserved Ejection Fraction in the community

[$50,000 per year for 2 years, total $100,000]                                                   Role: Principal Investigator